Open AccessSystemically administered collagen‐targeted gold nanoparticles bind to arterial injury following vascular interventions
Author(s) -
Meyers Molly Wasserman,
Rink Jonathan S.,
Jiang Qun,
Kelly Megan E.,
Vercammen Janet M.,
Thaxton Colby S.,
Kibbe Melina R.
Publication year - 2017
Publication title -
physiological reports
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 39
ISSN - 2051-817X
DOI - 10.14814/phy2.13128
Subject(s) - restenosis , medicine , biocompatibility , neointimal hyperplasia , systemic administration , colloidal gold , in vivo , pathology , pharmacology , chemistry , nanoparticle , nanotechnology , materials science , stent , biology , microbiology and biotechnology , organic chemistry
Surgical and endovascular therapies for severe atherosclerosis often fail due to the development of neointimal hyperplasia and arterial restenosis. Our objective was to synthesize, characterize, and evaluate the targeting specificity and biocompatibility of a novel systemically injected nanoparticle. We hypothesize that surface‐functionalization of gold nanoparticles (Au NP s) with a collagen‐targeting peptide will be biocompatible and target specifically to vascular injury. 13 nm Au NP s were surface functionalized with a peptide‐molecular fluorophore and targeted to collagen (T‐Au NP ) or a scrambled peptide sequence (S‐Au NP ). After rat carotid artery balloon injury and systemic injection of T‐Au NP or S‐Au NP , arteries and organs were harvested and assessed for binding specificity and biocompatibility. The T‐Au NP bound with specificity to vascular injury for a minimum of 24 h. No significant inflammation was evident locally at arterial injury or systemically in major organs. The T‐Au NP did not impact endothelial cell viability or induce apoptosis at the site of injury in vivo. No major changes were evident in hepatic or renal blood chemistry profiles. Herein, we synthesized a biocompatible nanoparticle that targets to vascular injury following systemic administration. These studies demonstrate proof‐of‐principle and serve as the foundation for further T‐Au NP optimization to realize systemic, targeted delivery of therapeutics to the sites of vascular injury.